Intravenous Labetalol Versus Hydralazine in Preeclampsia

Phase 1

Recruiting

• Conditions: Preeclampsia Severe
• Interventions: Drug: Labetalol Injection; Drug: HydrALAZINE Injection

• Registration Number: NCT06360601
• Lead Sponsor: Tanta University

Brief Summary

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-31
• Status Verified: 2024-04
• Study Start: 2024-04-01
• Study First Submitted QC: 2024-04-07
• Study First Posted: 2024-04-11
• Primary Completion: 2024-11-20
• Last Update Submitted: 2024-11-26
• Last Update Posted: 2024-12-02
• Study Completion: 2024-12-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• patient with clinical diagnosis of sever preeclampsia

Exclusion Criteria

Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Labetalol group	Labetalol Injection	-
Hydralazine group	HydrALAZINE Injection	-

Primary Outcome Measures

Name	Time	Method
Cerebral blood flow	Pre intervention-after one hour of intervention	Mean cerebral blood flow and cerebral perfusion pressure

Trial Locations

Locations (1)

Tanta Univeristy hospitals; 🇪🇬 Tanta, Egypt